Utility of smooth muscle actin and CD117 as reliable markers in the diagnosis of salivary gland neoplasms.
Myoepithelial
myofibroblast
pleomorphic adenoma
smooth muscle actin
Journal
Journal of oral and maxillofacial pathology : JOMFP
ISSN: 0973-029X
Titre abrégé: J Oral Maxillofac Pathol
Pays: India
ID NLM: 101227995
Informations de publication
Date de publication:
Historique:
entrez:
14
9
2019
pubmed:
14
9
2019
medline:
14
9
2019
Statut:
ppublish
Résumé
The aim of this study is to analyze the utility of immunohistochemical markers such as CD117 and smooth muscle actin (SMA) in the diagnosis of various benign and malignant salivary gland neoplasms. The study comprises 17 samples categorized into three groups: Group I consisted of 5 histopathologically normal salivary gland tissue; Group II comprised 7 cases, of which 3 cases were pleomorphic adenoma, 3 cases were myoepithelioma and 1 case was Warthin's tumor; and Group III consisted of 5 cases, of which 1 was mucoepidermoid carcinoma and 4 cases were adenoid cystic carcinoma. The selected cases were subjected to immunohistochemistry (IHC) procedure to assess the expression pattern of CD117 and SMA. In SMA, 85.8% showed severe-to-moderate intense expression among the tumor cells in benign salivary gland tumor. All the 5 malignant tumors showed the expression of SMA and 3 cases demonstrated severe expression among the tumor cells. An intense expression pattern of SMA was observed in both benign and malignant neoplasms in the periphery and stromal components of the tumor. Only two cases were positive for CD117, and connective tissue components were completely negative in both malignant and benign salivary gland neoplasms. Alpha-SMA can be utilized as reliable IHC markers for salivary gland neoplasms due to its diagnostic importance in tumors with myoepithelial origin indicative of the histogenesis of salivary gland tumors.
Identifiants
pubmed: 31516227
doi: 10.4103/jomfp.JOMFP_225_18
pii: JOMFP-23-218
pmc: PMC6714258
doi:
Types de publication
Journal Article
Langues
eng
Pagination
218-223Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
West Afr J Med. 1999 Jul-Sep;18(3):179-82
pubmed: 10593153
Cancer Lett. 2000 Jun 1;154(1):107-11
pubmed: 10799746
J Orthop Res. 2002 May;20(3):622-32
pubmed: 12038640
Mod Pathol. 2002 Jul;15(7):687-91
pubmed: 12118104
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 May;95(5):586-93
pubmed: 12738950
Oncogene. 1992 Jul;7(7):1259-66
pubmed: 1377810
Prog Histochem Cytochem. 2003;38(4):343-426
pubmed: 14509196
Mod Pathol. 2003 Dec;16(12):1224-31
pubmed: 14681323
Adv Anat Pathol. 2004 Mar;11(2):69-85
pubmed: 15090843
Cancer. 2004 Aug 25;102(4):207-9
pubmed: 15368311
Int J Surg Pathol. 2005 Jan;13(1):57-65
pubmed: 15735856
Oral Oncol. 2005 Oct;41(9):934-9
pubmed: 16054424
Oral Oncol. 2006 Jan;42(1):57-65
pubmed: 16140564
Mol Reprod Dev. 2006 Apr;73(4):399-403
pubmed: 16432822
J Oral Maxillofac Surg. 2006 Mar;64(3):415-23
pubmed: 16487803
J Clin Pathol. 2007 Mar;60(3):315-20
pubmed: 16698948
Oral Oncol. 2006 Nov;42(10):1011-6
pubmed: 16757205
Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):217-9
pubmed: 16785793
Oral Oncol. 2007 Jan;43(1):67-76
pubmed: 16807072
Oral Oncol. 2008 Apr;44(4):407-17
pubmed: 17825603
J Oral Maxillofac Surg. 2007 Nov;65(11):2187-94
pubmed: 17954313
J Oral Pathol Med. 2009 Sep;38(8):639-43
pubmed: 19473444
Head Neck Pathol. 2007 Sep;1(1):27-32
pubmed: 20614277
Mod Pathol. 2012 Jul;25(7):919-29
pubmed: 22460810
Acta Histochem Cytochem. 2012 Oct 31;45(5):269-82
pubmed: 23209336
EMBO J. 1987 Nov;6(11):3341-51
pubmed: 2448137
Cell Tissue Res. 2016 Aug;365(2):357-66
pubmed: 26979829
J Oral Pathol. 1984 Aug;13(4):342-58
pubmed: 6432979
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Mar;79(3):330-41
pubmed: 7542546
Mod Pathol. 1997 Nov;10(11):1093-100
pubmed: 9388059